Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has completed the acquisit...
Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network – Pr...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...
Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research ONE BioHub provides Scott...
Sarepta Therapeutics, Inc. the leader in precision genetic medicine for rare diseases, announced an update to the prescribing information for ELEVI...
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FD...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
Launched its first Asia office to support biotech and healthtech innovation and collaboration within the region The Asia office will house the Angelin...
Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...
AtomVie Global Radiopharma (AtomVie), a leading radiopharmaceutical CDMO, announced that it has successfully supplied the first dose of Ariceum The...
Continued uncertainty in the US has many of the world's top scientists considering the Basel area. Between the government shutdown, crippling inte...
GenomOncology announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain canc...
LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...
Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...
© 2025 Biopharma Boardroom. All Rights Reserved.
